ALNYLAM PHARMACEUTICALS, INC.
•1178670
Alnylam is a biopharmaceutical company focused on RNAi therapeutics. They develop and commercialize medicines for genetic diseases. Their key products address areas like amyloidosis, acute hepatic porphyria, and primary hyperoxaluria. Alnylam is a pioneer in the field of RNAi, recognized for scientific advancements and patient access initiatives.
90
Meget PåliteligOffisielt Register
AI Kvalitetsanalyse
Tillitsscore Detaljer
Register Verifisert35/35
Kvalitetsscore55/60
Nyhetsanalyse0/5
Snarveier
Nettside Høydepunkter
About Alnylam® Pharmaceuticals
Discover how Alnylam is using Nobel Prize-winning science to lead the translation of RNA interference (RNAi) into a new, innovative class of medicines.
siRNA Delivery: GalNAc Conjugates and LNPs | Alnylam® Pharmaceuticals
Alnylam's RNAi therapeutics use novel delivery methods including lipid nanoparticles (LNPs) and conjugates to deliver our siRNAs-based medicines to target tissu
Press Releases | Alnylam Pharmaceuticals, Inc.
Read our most recent press releases and search through our archive of releases.
Capella - RNAi Innovation and News
Capella is Alnylam's destination for RNAi news and innovation. Learn about the scientific progress Alnylam is making in RNAi to develop innovative medicines for
How RNAi Works | Alnylam® Pharmaceuticals
Learn how RNAi therapeutics work and utilize small interfering RNA (siRNA) to silence genes that cause, or contribute to disease.
Sist oppdatert: 12/31/2025
🌟 Lignende Pålitelige Bedrifter
GTP BIOWAYS CDMO
G
76/100 · Pålitelig
OLON France er en erfaren CDMO som betjener biofarmasøytisk industri. De tilbyr et bredt spekter av tjenester, inkludert prosessutvikling, GMP-produksjon og analytisk utvikling for biologiske legemidler. Deres ekspertise omfatter produksjon i pattedyrceller, mikrobielle systemer og biokonjugater, noe som posisjonerer dem som en allsidig partner for legemiddelutvikling.
ACTISUD 18 RUE JEAN PERRIN 31100 TOULOUSE, Frankrike